Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

First International Summit on Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Apr

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden

PSMA PET-CT Scan Reduces Need for Prostate Cancer Biopsies

Surgery Still Safe Beneficial For Many Octogenarian Patients With NSCLC

Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors

NCCN Names New Chief Scientific Officer